BluSky Carbon's Vulcan Heavy system at its AR1 plant in Arkansas
(Source: BluSky Carbon)
  • Renewable energy stock BluSky Carbon (CSE:BSKY) has initiated biochar production at its AR1 facility in Warren, Arkansas
  • The facility will deliver on a recently announced 10-year, US$105 million supply agreement with a U.S. customer
  • BluSky is a renewable energy stock that converts organic and industrial waste into biochar, renewable power and carbonate rocks
  • BluSky Carbon stock has given back 19.51 per cent since inception in June 2024

Renewable energy stock BluSky Carbon (CSE:BSKY) has initiated biochar production at its AR1 facility in Warren, Arkansas, to deliver on a recently announced 10-year, US$105 million supply agreement with a U.S. customer.

The company has started up one of three units deploying its Vulcan Heavy biochar production system, which is also designed to collect crude bio-oil and capture biosyngas for power generation. Once all three units are operational, the facility is expected to generate 40,000 tons of biochar per year.

According to Tuesday’s news release, Warren’s sustainable timber industry will provide “a nearly limitless source of clean biomass feedstock” for the facility, while nearby access to agricultural end-users will enhance efficiency and limit transportation costs for additional potential offtake agreements.

BluSky released a video in conjunction with the news release offering insights into the facility, its location and the company’s strategic plan.

Leadership insights

“The facility is ideally suited for scalability. We have ample room for the three Vulcan Heavy units as required to service our initial regional contract, with additional room to double that production without the need to create more space. The property itself is large and well-suited to handle industrial-scale logistics and storage needs,” Will Hessert, BluSky’s chief executive officer, said in a statement. 

“We are very excited to get this project underway. Gigaton-scale carbon removal cannot happen without industrial-scale carbon removal projects,” Hessert added. “The Warren AR1 operation showcases our ability to rapidly deploy large-scale carbon removal facilities. Additionally, we intend to grow the project by showcasing the potential opportunities which we believe will attract local, regional and even global interest. Beyond the immediate goals, we intend to use AR1 as a research facility to test novel technologies we hope to unveil in the months ahead. It’s extremely gratifying to build a project that moves our business forward while helping address a global issue. We are proud of what we are doing here today and look forward to building a successful venture on the back of this launch today.”

About BluSky Carbon 

BluSky is a renewable energy stock that converts organic and industrial waste into biochar, renewable power and carbonate rocks.

BluSky Carbon stock (CSE:BSKY) last traded at C$0.66 per share. The stock has given back 19.51 per cent since inception in June 2024.

Join the discussion: Find out what everybody’s saying about this renewable energy stock achieving biochar production on the BluSky Carbon Inc. Bullboard and check out the rest of Stockhouse’s stock forums and message boards.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.

(Top photo of BluSky Carbon’s Vulcan Heavy system at its AR1 plant in Arkansas: BluSky Carbon)


More From The Market Online
AI generated stock image of stock tickers on skyscrapers.

@ the Bell: TSX blows past all-time high

The TSX reached a new record high on Thursday, even though there were early declines among significant sectors.
E3 Lithium's direct lithium extraction pilot plant in 2023

E3 inches closer to Alberta’s first lithium production plant

E3 Lithium (TSXV:ETL) secures an option on a brownfield site for its Clearwater project’s central processing facility.
image of scientist looking into a microscope

BriaCell begins phase 1/2 trial of Bria-OTS™ for breast cancer

BriaCell Therapeutics (TSX:BCT) initiates a Phase 1/2 clinical trial of Bria-OTS for metastatic breast cancer.